Skip to main content

Table 2 Primary and secondary outcomes

From: Metoclopramide or domperidone improves post-pyloric placement of spiral nasojejunal tubes in critically ill patients: a prospective, multicenter, open-label, randomized, controlled clinical trial

  Metoclopramide group Domperidone group Control group P value
( n = 100) ( n = 99) ( n = 99)
Tube tip position     
 Post-pyloric 55 (55.0)** 51 (51.5)** 27 (27.3) 0.0001
 Post-D1 47 (47.0)** 44 (44.4)** 24 (24.2) 0.0015
 Post-D2 34 (34.0)** 40 (40.4)** 13 (13.1) 0.0001
 Post-D3 27 (27.0)* 26 (26.3)* 11 (11.1) 0.0088
 Proximal jejunum 19 (19.0) 16 (16.2) 10 (10.1) 0.2016
Tube migration distance     
 Initial nose scale (cm) 75.3 ± 7.5 75.1 ± 7.0 75.2 ± 7.1 0.9708
 Nose scale at 24 hours (cm) 86.1 ± 10.3 84.9 ± 10.3 80.6 ± 8.9 0.0003
 Migration distance (cm) 10.8 ± 8.1 9.8 ± 8.5 5.5 ± 7.6 0.0001
  1. Data presented as mean ± standard deviation or n (%). Post-pyloric, reaching the first portion of the duodenum or beyond. Post-D1, reaching the second portion of the duodenum or beyond. Post-D2, reaching the third portion of the duodenum or beyond. Post-D3, reaching the fourth portion of the duodenum or beyond. *P <0.016, metoclopramide group versus controls or domperidone group versus controls. **P <0.003, metoclopramide group versus controls or domperidone group versus controls. P <0.01, metoclopramide group versus controls or domperidone group versus controls.